Can-Fite BioPharma Ltd. (CANF)
| Previous Close | 0.9118 |
| Open | 0.8844 |
| Bid | 0.8800 x 1200 |
| Ask | 0.8903 x 1200 |
| Day's Range | 0.8710 - 0.8999 |
| 52 Week Range | 0.7800 - 2.6000 |
| Volume | |
| Avg. Volume | 134,345 |
| Market Cap | 23.929M |
| Beta (5Y Monthly) | 1.65 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.7500 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.85 |
- Business Wire
Can-Fite’s CF602 Reverses Erectile Dysfunction in Diabetic Pre-clinical Model: Study Published in Peer-Reviewed Journal Andrologia
PETACH TIKVA, Israel, June 24, 2022--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced its study titled "A3 adenosine receptor allosteric modulator CF602 reverses erectile dysfunction in a diabetic rat model" was published in the peer-reviewed journal Andrologia.
- Business Wire
Can-Fite Announces Publication of Clinical Study Data for Piclidenoson and Namodenoson in Scientific Journal
PETACH TIKVA, Israel, June 09, 2022--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced an article titled "Drugs Targeting the A3 Adenosine Receptor: Human Clinical Study Data" was published in MDPI’s open access scholarly journal Molecules. The complete article can be accessed here: LINK
- Business Wire
Can-Fite Reports First Quarter 2022 Financial Results & Provides Clinical Update
PETACH TIKVA, Israel, May 26, 2022--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced financial results for the quarter ended March 31, 2022.
